semaglutide and cardiovascular disease National Consensus on in Cardiology: From Clinical Evidence to Clinical Translation Semaglutide and Cardiovascular Health |

Learn more at casadesante.com

Scientifically Backed for Real Results: Clinical studies show that 10g (the amount in 4 tsp) helps promote satiety within 30 minutes after a meal and helps maintain appetite control for up to 4 hours.* Designed for convenient daily use

Free peptide reconstitution and dosage calculators

Learn expert tips on timing your dose for better results.

The FDA has approved glucagon-like peptide-1 (GLP-1) receptor agonists such as Liraglutide, Semaglutide, and the GLP-1/gastric inhibitory polypeptide (GIP) dual agonist Tirzepatide for the treatment of obesity

A new study has found that Wegovy, an obesity treatment drug recently launched in South Korea, is also effective for knee arthritis